(HealthDay News) — There is considerable interindividual variation in the magnitude of LDL, non-HDL and apolipoprotein B reductions achieved with statin therapy, which affects cardiovascular disease risk, according to a study published in the Journal of the American College of Cardiology.
S. Matthijs Boekholdt, MD, PhD, from the Academic Medical Center in Amsterdam, and colleagues conducted a meta-analysis using individual patient data from eight randomized controlled statin trials. Data were included for 38,153 patients who were allocated to statin therapy, and underwent assessment for conventional lipids and apolipoproteins at baseline and at 1-year follow-up.
The researchers found that 5,287 participants had 6,286 major cardiovascular (CV) events during follow-up. Reductions of LDL, non-HDL, and apolipoprotein B (apoB) were subject to large interindividual variability despite a fixed statin dose.
More than 40% of those assigned to high-dose statins did not achieve an LDL target of <70 mg/dL. The adjusted hazard ratios for major CV events were 0.56, 0.51 and 0.44, respectively, for those who reached an LDL of 75 to <100 mg/dL, 50 to <75 mg/dL and <50 mg/dL vs. LDL >175 mg/dL.
The findings were similar for non-HDL and apoB.
“Patients who achieve very low LDL levels have a lower risk for major CV events than do those achieving moderately low levels,” the researchers concluded.
Several authors disclosed financial ties to the pharmaceutical industry.